Other analysts have also issued reports about the company. Cann reiterated a buy rating and set a $13.00 price target on shares of Verastem in a report on Friday, January 26th. Oppenheimer set a $13.00 price target on Verastem and gave the stock a buy rating in a report on Thursday, December 21st. HC Wainwright set a $10.00 price target on Verastem and gave the stock a buy rating in a report on Wednesday, December 13th. Raymond James Financial reiterated a buy rating on shares of Verastem in a report on Monday, December 11th. Finally, Zacks Investment Research upgraded Verastem from a hold rating to a buy rating and set a $3.75 price target on the stock in a report on Saturday, March 17th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The company presently has an average rating of Buy and an average price target of $10.14.
Shares of Verastem stock opened at $3.77 on Monday. The firm has a market cap of $166.63, a P/E ratio of -2.14 and a beta of 2.23. Verastem has a 12 month low of $1.61 and a 12 month high of $5.71. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.13 and a current ratio of 5.13.
Several institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC raised its stake in shares of Verastem by 92.8% in the fourth quarter. Millennium Management LLC now owns 357,615 shares of the biopharmaceutical company’s stock valued at $1,098,000 after buying an additional 172,166 shares during the period. Two Sigma Investments LP raised its stake in shares of Verastem by 133.7% in the fourth quarter. Two Sigma Investments LP now owns 261,771 shares of the biopharmaceutical company’s stock valued at $804,000 after buying an additional 149,744 shares during the period. Two Sigma Advisers LP bought a new stake in shares of Verastem in the fourth quarter valued at $231,000. BVF Inc. IL bought a new stake in shares of Verastem in the fourth quarter valued at $6,908,000. Finally, Stonepine Capital Management LLC bought a new stake in shares of Verastem in the fourth quarter valued at $691,000. Hedge funds and other institutional investors own 31.65% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Verastem (VSTM) Given a $17.00 Price Target at Cantor Fitzgerald” was posted by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://dakotafinancialnews.com/2018/04/12/verastem-vstm-given-a-17-00-price-target-at-cantor-fitzgerald.html.
Verastem Company Profile
Verastem, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.